Alcon v. Gland Pharma: Olopatadine Eye Drop Patents — Voluntarily Dismissed
Alcon Inc. and Alcon Laboratories, Inc. filed suit against Gland Pharma, Ltd. in Delaware, asserting two patents covering high concentration olopatadine ophthalmic compositions. The plaintiffs voluntarily dismissed the action under Rule 41(a) just 64 days after filing.
Alcon moves fast: two olopatadine patents, one swift exit
On 20 March 2023, Alcon Inc. and Alcon Laboratories, Inc. filed an infringement action in the Delaware District Court against Gland Pharma, Ltd., an Indian generic pharmaceutical manufacturer. The complaint asserted two U.S. patents — US9533053B2 and US8791154B2 — both directed to high concentration olopatadine ophthalmic compositions, a product class used to treat allergic conjunctivitis. The case was assigned to Judge Gregory B. Williams. No defendant agents or law firm are recorded in the available docket.
The recorded basis of termination is Voluntary dismissal. The docket order states that, pursuant to Rule 41(a) of the Federal Rules of Civil Procedure, Alcon dismissed the action with prejudice. The specific terms underlying the dismissal are not disclosed in the available public record.
The case closed on 23 May 2023, just 64 days after filing — a notably brief litigation window that suggests the parties reached an understanding early in the proceedings. What drove the swift resolution, and whether any commercial arrangement accompanied it, is not reflected in the public record.
See Complete Case & Patent Analysis →Filing to Voluntary dismissal in 64 days
Case resolved in 64 days — well under median ANDA patent litigation timelines
US9533053B2 & US8791154B2 — High Concentration Olopatadine Ophthalmic Compositions
Any company developing, manufacturing, or commercialising high concentration olopatadine ophthalmic products in the United States should treat these two patents as live risk assets. The dismissal of the Gland Pharma action does not invalidate or limit the patents' claims — it simply removes Gland Pharma from the enforcement picture. ANDA filers, contract development and manufacturing organisations working in ophthalmic formulations, and branded competitors reformulating olopatadine products are all within the potential enforcement perimeter.
Official order — verbatim text
The Rule 41(a) notice records a plaintiff-initiated dismissal with prejudice, which functions as a final bar to Alcon reasserting these specific claims against Gland Pharma. No merits determination was reached, and the court made no finding on infringement, validity, or claim scope. The specific circumstances prompting the dismissal are not disclosed in the available docket record.
Voluntarily dismissed: what the Rule 41(a) exit means for both parties
Rule 41(a) voluntary dismissal: plaintiff-initiated exit
Under Federal Rule of Civil Procedure 41(a), a plaintiff may dismiss an action without a court order by filing a notice or stipulation. The docket records this as a voluntary dismissal. The verdict text states the dismissal was with prejudice, meaning Alcon cannot re-file the same claims against Gland Pharma on these two patents. The specific terms motivating the dismissal are not disclosed in the available record.
Plaintiff-initiated exitThe with-prejudice designation carries real legal weight
A dismissal with prejudice operates as a final adjudication on the merits, barring Alcon from reasserting the same patent claims against Gland Pharma in a future action. A dismissal without prejudice would leave the door open to re-filing. The basis of termination is recorded as 'Voluntary dismissal' without specifying either designation; the verdict text states 'with prejudice.' The public record does not disclose what prompted Alcon to accept a with-prejudice outcome.
With prejudice — re-filing barredAlcon exits but the underlying patents remain in force
The voluntary dismissal resolves this particular action against Gland Pharma, but US9533053B2 and US8791154B2 remain granted and enforceable patents. Alcon retains the right to assert them against other parties. The dismissal with prejudice applies only to these claims against this defendant; its commercial rationale is not reflected in the docket.
Patents remain in forceGland Pharma cleared — but market entry terms are undisclosed
The dismissal removes the patent infringement bar to Gland Pharma's potential market entry for high concentration olopatadine ophthalmic products, at least as these two patents are concerned. Whether any licensing arrangement, market-entry schedule, or other commercial condition was agreed between the parties is not disclosed in the available record. Other generic entrants in this product space should note that the patents themselves have not been invalidated or found not infringed.
Gland Pharma cleared on these patentsFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Alcon, Inc. | Company | /Search in Eureka ↗ |
| Co-Plaintiff | Alcon Laboratories, Inc. | Company | Search in Eureka ↗ |
| Defendant | Gland Pharma, Ltd. | Company | /Search in Eureka ↗ |
| Plaintiff counsel | Alexandra M. Joyce | Attorney | Counsel for Alcon, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Daniel M. Silver | Attorney | Counsel for Alcon, Inc.Search in Eureka ↗ |
| Plaintiff law firm | McCarter & English, LLP | Law Firm | Representing Alcon, Inc.Search in Eureka ↗ |
| Presiding judge | Judge Gregory B. Williams | Judge | Delaware District CourtSearch in Eureka ↗ |
R&D signals in the ophthalmic formulation space
Forward-looking patent and innovation intelligence derived from Alcon's olopatadine enforcement action and the broader high concentration ophthalmic formulation landscape.
Alcon's ophthalmic formulation patent estate beyond olopatadine
Alcon holds multiple patent families across ophthalmic active ingredients, formulation technologies, and delivery systems. Mapping Alcon's filing activity in high concentration topical eye drop formulations can reveal how broadly its exclusivity extends beyond the two asserted patents and where adjacent product lines may face similar enforcement risk.
Alcon ophthalmic IP portfolioFiling trends in high concentration olopatadine ophthalmic formulations
Patent filing activity around olopatadine formulation — covering concentration ranges, excipient combinations, preservative systems, and bioavailability enhancement — can signal where innovation is clustering and where formulation design-around space may be available to generic and biosimilar developers entering this product category.
Olopatadine formulation filing trendsGland Pharma's ophthalmic patent and ANDA filing activity
Gland Pharma is an established generic injectable and ophthalmic manufacturer. Tracking its ANDA submissions and patent challenge history in the ophthalmic category can reveal which product areas it is actively pursuing and how its IP posture is evolving in response to enforcement actions from branded players like Alcon.
Gland Pharma ophthalmic IPFormulation design-around opportunities in ophthalmic antihistamines
The concentration and excipient claim architecture of US9533053B2 and US8791154B2 may leave formulation white space for developers working on alternative delivery vehicles, preservative-free systems, or combination antihistamine products. A claim-gap analysis against the broader ophthalmic antihistamine patent landscape can identify R&D vectors that avoid Alcon's exclusivity.
Ophthalmic antihistamine white spaceSimilar ophthalmic pharmaceutical patent cases in Delaware District Court
Cases involving branded ophthalmic formulation patents asserted against generic manufacturers in the Delaware District Court, including olopatadine and related topical drug products.
What this case signals for the ophthalmic pharmaceutical IP landscape
A 64-day lifecycle on a two-patent ophthalmic infringement action in Delaware raises questions every generic manufacturer in this space should examine.
Swift voluntary dismissals in ANDA-adjacent cases are worth monitoring closely
When a branded pharmaceutical plaintiff dismisses with prejudice inside 64 days, it typically signals that the litigation served a purpose beyond the courtroom — whether that is a licensing conversation, a market-entry agreement, or a strategic reassessment. Competitors and generic entrants in the olopatadine space should track whether similar actions follow against other ANDA filers.
US9533053B2 and US8791154B2 remain active enforcement tools
The dismissal applies only to Gland Pharma. Both patents remain granted and enforceable. Any manufacturer or formulator working in the high concentration olopatadine ophthalmic composition space should conduct a freedom-to-operate analysis against these two assets before advancing a product toward commercialisation.
Alcon v Gland — key questions answered
Alcon asserted two U.S. patents: US9533053B2 (application no. US14/304124) and US8791154B2 (application no. US13/475607). Both patents cover high concentration olopatadine ophthalmic compositions, a product class used to treat allergic conjunctivitis.
The recorded basis of termination is Voluntary dismissal. The docket order states that Alcon dismissed the action with prejudice pursuant to Rule 41(a) of the Federal Rules of Civil Procedure. The specific terms are not disclosed in the available public record.
No. The voluntary dismissal resulted in no merits determination by the court. US9533053B2 and US8791154B2 were not found invalid or not infringed. Both patents remain granted and enforceable against other parties. Only these specific claims against Gland Pharma are barred by the with-prejudice dismissal.
Based on the verdict text, the dismissal was filed with prejudice under Rule 41(a). A with-prejudice dismissal operates as a final adjudication on the merits for these claims, which would bar Alcon from reasserting the same patent claims against Gland Pharma. The basis of termination is recorded as Voluntary dismissal; the public record does not disclose the specific terms.
The case was filed in the Delaware District Court and assigned to Judge Gregory B. Williams. It was filed on 20 March 2023 and closed on 23 May 2023, a total of 64 days.
This page is compiled from public court dockets and third-party patent and litigation data via PatSnap Eureka, and is provided for general informational purposes only. The information shown — including party names, patent and application numbers, dates, case status, outcomes, and any analysis — may be incomplete, may not reflect the most recent filings or legal status, and may contain errors or omissions. Verify all details against official court records (for example, PACER) and the relevant patent office before relying on them.
Nothing on this page constitutes legal advice or a legal opinion on the validity, infringement, enforceability, or scope of any patent or case, and no attorney‑client relationship is created by its use. Any description of an outcome (such as a dismissal, settlement, or consent judgment) is a general summary, not a legal determination. All patents, trademarks, and company or law‑firm names are the property of their respective owners. PatSnap makes no warranty as to the accuracy or completeness of this content and disclaims, to the fullest extent permitted by law, all liability for reliance on it. For advice on a specific matter, consult qualified legal counsel.
PatSnap Eureka searches patents and litigation data to answer instantly.